23:
885:
de Voogt HJ, Studer U, Schröder FH, Klijn JG, de Pauw M, Sylvester R (1998). "Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced
678:
de Voogt HJ, Smith PH, Pavone-Macaluso M, de Pauw M, Suciu S (February 1986). "Cardiovascular side effects of diethylstilbestrol, cyproterone acetate, medroxyprogesterone acetate and estramustine phosphate used for the treatment of advanced prostatic cancer: results from
European Organization for
323:
Beex L, Rose C, Mouridsen H, Jassem J, Nooij M, Estape J, et al. (December 2006). "Continuous versus intermittent tamoxifen versus intermittent/alternated tamoxifen and medroxyprogesterone acetate as first line endocrine treatment in advanced breast cancer: an EORTC phase III study (10863)".
749:
Robinson MR, Smith PH, Richards B, Newling DW, de Pauw M, Sylvester R (1995). "The final analysis of the EORTC Genito-Urinary Tract Cancer Co-Operative Group phase III clinical trial (protocol 30805) comparing orchidectomy, orchidectomy plus cyproterone acetate and low dose stilboestrol in the
619:
Pavone-Macaluso M, Schröder FH, de Voogt HJ, Viggiano G, Barasolo E, Lardennois B, et al. (1989). "EORTC protocol 30761: a randomized study of non-metastatic and metastatic prostatic cancer treated by cyproterone acetate versus diethylstilbestrol and medroxyprogesterone acetate. European
1133:
Schröder FH, Whelan P, de Reijke TM, Kurth KH, Pavone-Macaluso M, Mattelaer J, et al. (April 2004). "Metastatic prostate cancer treated by flutamide versus cyproterone acetate. Final analysis of the "European
Organization for Research and Treatment of Cancer" (EORTC) Protocol 30892".
361:"The effect of exemestane on serum lipid profile in postmenopausal women with metastatic breast cancer: a companion study to EORTC Trial 10951, 'Randomized phase II study in first line hormonal treatment for metastatic breast cancer with exemestane or tamoxifen in postmenopausal patients'"
841:
de Voogt HJ, Klijn JG, Studer U, Schröder F, Sylvester R, De Pauw M (December 1990). "Orchidectomy versus
Buserelin in combination with cyproterone acetate, for 2 weeks or continuously, in the treatment of metastatic prostatic cancer. Preliminary results of EORTC-trial 30843".
1169:
Kil PJ, Goldschmidt HM, Wieggers BJ, Kariakine OB, Studer UE, Whelan P, et al. (January 2003). "Tissue polypeptide-specific antigen (TPS) determinations before and during intermittent maximal androgen blockade in patients with metastatic prostatic carcinoma".
647:
Pavone-Macaluso M, Ingargiola GB, de Voogt H, Viggiano G, Barasolo E, Lardennois B, et al. (1987). "Cyproterone acetate versus medroxyprogesterone acetate versus diethylstilbestrol in the treatment of prostate cancer: results from EORTC Study 30761".
1005:
Denis LJ, Keuppens F, Smith PH, Whelan P, de Moura JL, Newling D, et al. (1998). "Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer
Cooperative Group and the EORTC Data Center".
813:
Robinson MR (1987). "Complete androgen blockade: the EORTC experience comparing orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose stilboestrol in the treatment of metastatic carcinoma of the prostate".
785:
Robinson MR (1988). "EORTC protocol 30805: a phase III trial comparing orchidectomy versus orchidectomy and cyproterone acetate and low dose stilboestrol in the management of metastatic carcinoma of the prostate".
1255:
Albrecht W, Collette L, Fava C, Kariakine OB, Whelan P, Studer UE, et al. (November 2003). "Intermittent maximal androgen blockade in patients with metastatic prostate cancer: an EORTC feasibility study".
714:
Smith PH, Robinson M, Richards B, Suciu S, De Pauw M, Sylvester R, Denis L (June 1984). "Estramustine phosphate in prostate cancer. EORTC experience: preliminary results of
Protocol 30762".
58:
929:
Carvalho AP, de Moura JL, Denis L, Newling D, Smith P, Bono A, et al. (1989). "Zoladex and flutamide vs orchidectomy: a phase III EORTC 30853 trial. EORTC Urological Group".
886:
prostate cancer. Final analysis of EORTC GU Group Trial 30843. European
Organization for Research and Treatment of Cancer (EROTC) Genito-Urinary Tract Cancer Cooperative Group".
1098:
Collette L, de Reijke TM, Schröder FH (August 2003). "Prostate specific antigen: a prognostic marker of survival in good prognosis metastatic prostate cancer? (EORTC 30892)".
1051:"Prostate cancer treated by anti-androgens: is sexual function preserved? EORTC Genitourinary Group. European Organization for Research and Treatment of Cancer"
233:
234:"Pathological characterisation of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program"
592:
Pavone-Macaluso M, Lund F, Mulder JH, Smith PH, De Pauw M, Sylvester R (1980). "EORTC protocols in prostatic cancer. An interim report".
276:"Characterization of male breast cancer: results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program"
511:
Denis L (May 1998). "European
Organization for Research and Treatment of Cancer (EORTC) prostate cancer trials, 1976-1996".
133:
81:
30:
212:
201:
958:"Zoladex and flutamide versus bilateral orchiectomy. A randomized phase III EORTC 30853 study. The EORTC GU Group"
546:
Bollack C, Rougeron G (1988). "Hormonal therapy trials in prostatic cancer. An EORTC Genitourinary Group study".
1297:
274:
Cardoso F, Bartlett JM, Slaets L, van
Deurzen CH, van Leeuwen-Stok E, Porter P, et al. (February 2018).
232:
Vermeulen MA, Slaets L, Cardoso F, Giordano SH, Tryfonidis K, van Diest PJ, et al. (September 2017).
144:
400:
Heuson JC, Engelsman E, Blonk-Van Der Wijst J, Maass H, Drochmans A, Michel J, et al. (June 1975).
449:
Engelsman E, Heuson JC, Blonk Van Der Wijst J, Drochmans A, Maass H, Cheix F, et al. (June 1975).
402:"Comparative trial of nafoxidine and ethinyloestradiol in advanced breast cancer: an E.O.R.T.C. study"
451:"Controlled clinical trial of L-dopa and nafoxidine in advanced breast cancer: an E.O.R.T.C. study"
184:
159:
129:
1237:
1031:
987:
911:
867:
571:
163:
148:
137:
71:
1273:
1229:
1187:
1151:
1115:
1080:
1023:
979:
938:
903:
859:
823:
795:
767:
731:
696:
657:
629:
601:
563:
528:
480:
431:
382:
341:
305:
256:
1265:
1221:
1179:
1143:
1107:
1070:
1062:
1015:
969:
956:
Keuppens F, Denis L, Smith P, Carvalho AP, Newling D, Bond A, et al. (September 1990).
895:
851:
759:
723:
688:
555:
520:
470:
462:
421:
413:
372:
333:
295:
287:
248:
104:
359:
Atalay G, Dirix L, Biganzoli L, Beex L, Nooij M, Cameron D, et al. (February 2004).
1206:
1075:
1050:
475:
450:
426:
401:
300:
275:
1269:
1183:
1111:
727:
692:
524:
1291:
915:
855:
559:
1241:
1035:
991:
871:
575:
205:
1147:
974:
957:
155:
337:
252:
191:
113:
100:
87:
377:
360:
291:
195:
177:
170:
77:
1277:
1191:
1155:
1119:
1084:
1066:
466:
417:
386:
345:
309:
260:
80:
versus intermittent tamoxifen versus intermittent/alternated tamoxifen and
1233:
1027:
983:
942:
907:
863:
827:
799:
771:
735:
700:
661:
633:
605:
567:
532:
484:
435:
109:
124:
The following prostate cancer trials have been conducted, among others:
1225:
1019:
899:
763:
620:
Organization for
Research on Treatment of Cancer Urological Group".
1049:
Schröder FH, Collette L, de Reijke TM, Whelan P (January 2000).
1207:"Intermittent androgen deprivation in advanced prostate cancer"
17:
183:
EORTC 30892 – flutamide monotherapy (750 mg/day) versus
173:
versus buserelin plus cyproterone acetate (150 mg/day)
59:
844:
The Journal of Steroid Biochemistry and Molecular Biology
679:
Research on Treatment of Cancer trials 30761 and 30762".
34:
750:
management of metastatic carcinoma of the prostate".
147:280 mg/day (560 mg/day initially) versus
673:
671:
594:Scandinavian Journal of Urology and Nephrology
587:
585:
506:
504:
502:
500:
498:
496:
494:
8:
931:Progress in Clinical and Biological Research
816:Progress in Clinical and Biological Research
788:Progress in Clinical and Biological Research
650:Progress in Clinical and Biological Research
622:Progress in Clinical and Biological Research
1074:
973:
474:
425:
376:
299:
224:
548:American Journal of Clinical Oncology
7:
162:(150 mg/day) versus low-dose
70:EORTC 10085 – characterization of
14:
176:EORTC 30853 – orchiectomy versus
169:EORTC 30843 – orchiectomy versus
560:10.1097/00000421-198801102-00037
180:plus flutamide (750 mg/day)
21:
1:
1270:10.1016/s0302-2838(03)00375-0
1184:10.1016/s0302-2838(02)00499-2
1112:10.1016/s0302-2838(03)00251-3
728:10.1016/s0090-4295(84)80101-6
693:10.1016/s0022-5347(17)45620-5
525:10.1016/s0090-4295(98)00076-4
55:list of EORTC clinical trials
1148:10.1016/j.eururo.2003.11.016
1106:(2): 182–9, discussion 189.
975:10.1002/cncr.1990.66.s5.1045
856:10.1016/0960-0760(90)90451-p
211:EORTC 30958 – intermittent
200:EORTC 30954 – intermittent
134:medroxyprogesterone acetate
82:medroxyprogesterone acetate
1314:
338:10.1016/j.ejca.2006.08.020
326:European Journal of Cancer
253:10.1016/j.ejca.2017.01.034
241:European Journal of Cancer
213:combined androgen blockade
202:combined androgen blockade
1055:British Journal of Cancer
600:(Supplementum): 163–168.
76:EORTC 10863 – continuous
204:(with GnRH agonist plus
158:versus orchiectomy plus
455:British Medical Journal
406:British Medical Journal
136:200 mg/day versus
132:250 mg/day versus
1067:10.1054/bjoc.1999.0916
968:(5 Suppl): 1045–1057.
681:The Journal of Urology
554:(Suppl 2): S156–S159.
467:10.1136/bmj.2.5973.714
418:10.1136/bmj.2.5973.711
145:estramustine phosphate
1205:de Reijke TM (1997).
378:10.1093/annonc/mdh064
292:10.1093/annonc/mdx651
1220:(Suppl 2): S63–S66.
35:adding missing items
1214:Urological Research
519:(5A Suppl): 50–57.
185:cyproterone acetate
160:cyproterone acetate
130:cyproterone acetate
1226:10.1007/BF00941990
722:(6 Suppl): 64–68.
365:Annals of Oncology
280:Annals of Oncology
164:diethylstilbestrol
149:diethylstilbestrol
138:diethylstilbestrol
72:male breast cancer
33:; you can help by
1020:10.1159/000019546
900:10.1159/000019547
764:10.1159/000475067
461:(5973): 714–715.
412:(5973): 711–713.
332:(18): 3178–3185.
208:(50 mg/day))
187:(300 mg/day)
57:sponsored by the
51:
50:
1305:
1282:
1281:
1258:European Urology
1252:
1246:
1245:
1211:
1202:
1196:
1195:
1172:European Urology
1166:
1160:
1159:
1136:European Urology
1130:
1124:
1123:
1100:European Urology
1095:
1089:
1088:
1078:
1046:
1040:
1039:
1008:European Urology
1002:
996:
995:
977:
953:
947:
946:
926:
920:
919:
888:European Urology
882:
876:
875:
838:
832:
831:
810:
804:
803:
782:
776:
775:
752:European Urology
746:
740:
739:
711:
705:
704:
675:
666:
665:
644:
638:
637:
616:
610:
609:
589:
580:
579:
543:
537:
536:
508:
489:
488:
478:
446:
440:
439:
429:
397:
391:
390:
380:
356:
350:
349:
320:
314:
313:
303:
271:
265:
264:
238:
229:
105:ethinylestradiol
90:versus tamoxifen
46:
43:
25:
24:
18:
1313:
1312:
1308:
1307:
1306:
1304:
1303:
1302:
1298:Clinical trials
1288:
1287:
1286:
1285:
1254:
1253:
1249:
1209:
1204:
1203:
1199:
1168:
1167:
1163:
1132:
1131:
1127:
1097:
1096:
1092:
1048:
1047:
1043:
1004:
1003:
999:
955:
954:
950:
928:
927:
923:
884:
883:
879:
840:
839:
835:
812:
811:
807:
784:
783:
779:
748:
747:
743:
713:
712:
708:
677:
676:
669:
646:
645:
641:
618:
617:
613:
591:
590:
583:
545:
544:
540:
510:
509:
492:
448:
447:
443:
399:
398:
394:
358:
357:
353:
322:
321:
317:
273:
272:
268:
236:
231:
230:
226:
221:
166:(1 mg/day)
122:
120:Prostate cancer
97:
67:
53:This page is a
47:
41:
38:
22:
12:
11:
5:
1311:
1309:
1301:
1300:
1290:
1289:
1284:
1283:
1264:(5): 505–511.
1247:
1197:
1161:
1142:(4): 457–464.
1125:
1090:
1061:(2): 283–290.
1041:
1014:(2): 144–151.
997:
948:
921:
894:(2): 152–158.
877:
850:(6): 965–969.
833:
805:
777:
758:(4): 273–283.
741:
706:
687:(2): 303–307.
667:
639:
611:
581:
538:
490:
441:
392:
371:(2): 211–217.
351:
315:
286:(2): 405–417.
266:
223:
222:
220:
217:
216:
215:
209:
198:
190:EORTC 30903 –
188:
181:
174:
167:
154:EORTC 30805 –
152:
143:EORTC 30762 –
141:
128:EORTC 30761 –
121:
118:
117:
116:
107:
96:
93:
92:
91:
86:EORTC 10951 –
84:
74:
66:
63:
49:
48:
28:
26:
13:
10:
9:
6:
4:
3:
2:
1310:
1299:
1296:
1295:
1293:
1279:
1275:
1271:
1267:
1263:
1259:
1251:
1248:
1243:
1239:
1235:
1231:
1227:
1223:
1219:
1215:
1208:
1201:
1198:
1193:
1189:
1185:
1181:
1177:
1173:
1165:
1162:
1157:
1153:
1149:
1145:
1141:
1137:
1129:
1126:
1121:
1117:
1113:
1109:
1105:
1101:
1094:
1091:
1086:
1082:
1077:
1072:
1068:
1064:
1060:
1056:
1052:
1045:
1042:
1037:
1033:
1029:
1025:
1021:
1017:
1013:
1009:
1001:
998:
993:
989:
985:
981:
976:
971:
967:
963:
959:
952:
949:
944:
940:
936:
932:
925:
922:
917:
913:
909:
905:
901:
897:
893:
889:
881:
878:
873:
869:
865:
861:
857:
853:
849:
845:
837:
834:
829:
825:
821:
817:
809:
806:
801:
797:
793:
789:
781:
778:
773:
769:
765:
761:
757:
753:
745:
742:
737:
733:
729:
725:
721:
717:
710:
707:
702:
698:
694:
690:
686:
682:
674:
672:
668:
663:
659:
655:
651:
643:
640:
635:
631:
627:
623:
615:
612:
607:
603:
599:
595:
588:
586:
582:
577:
573:
569:
565:
561:
557:
553:
549:
542:
539:
534:
530:
526:
522:
518:
514:
507:
505:
503:
501:
499:
497:
495:
491:
486:
482:
477:
472:
468:
464:
460:
456:
452:
445:
442:
437:
433:
428:
423:
419:
415:
411:
407:
403:
396:
393:
388:
384:
379:
374:
370:
366:
362:
355:
352:
347:
343:
339:
335:
331:
327:
319:
316:
311:
307:
302:
297:
293:
289:
285:
281:
277:
270:
267:
262:
258:
254:
250:
246:
242:
235:
228:
225:
218:
214:
210:
207:
203:
199:
197:
193:
189:
186:
182:
179:
175:
172:
168:
165:
161:
157:
153:
151:3 mg/day
150:
146:
142:
140:3 mg/day
139:
135:
131:
127:
126:
125:
119:
115:
111:
108:
106:
102:
99:
98:
95:Older studies
94:
89:
85:
83:
79:
75:
73:
69:
68:
65:Breast cancer
64:
62:
60:
56:
45:
36:
32:
29:This list is
27:
20:
19:
16:
1261:
1257:
1250:
1217:
1213:
1200:
1178:(1): 31–38.
1175:
1171:
1164:
1139:
1135:
1128:
1103:
1099:
1093:
1058:
1054:
1044:
1011:
1007:
1000:
965:
961:
951:
934:
930:
924:
891:
887:
880:
847:
843:
836:
819:
815:
808:
791:
787:
780:
755:
751:
744:
719:
715:
709:
684:
680:
653:
649:
642:
625:
621:
614:
597:
593:
551:
547:
541:
516:
512:
458:
454:
444:
409:
405:
395:
368:
364:
354:
329:
325:
318:
283:
279:
269:
244:
240:
227:
206:bicalutamide
123:
54:
52:
39:
15:
937:: 129–143.
822:: 383–390.
794:: 101–110.
656:: 379–382.
628:: 111–116.
247:: 219–227.
156:orchiectomy
219:References
192:prednisone
114:nafoxidine
101:Nafoxidine
88:exemestane
42:March 2022
31:incomplete
916:209144445
196:flutamide
178:goserelin
171:buserelin
78:tamoxifen
61:(EORTC).
1292:Category
1278:14572746
1242:31327672
1192:12507541
1156:15041109
1120:12875936
1085:10646878
1036:13056714
992:23659092
872:13439306
576:20422041
387:14760111
346:17045796
310:29092024
261:28292559
110:Levodopa
1234:9144889
1076:2363280
1028:9519355
984:2144206
943:2528736
908:9519356
864:2149509
828:2958863
800:2966402
772:8575493
736:6375083
716:Urology
701:2935644
662:2958862
634:2528735
606:6938020
568:2977270
533:9610558
513:Urology
485:1095122
476:1673916
436:1095121
427:1673940
301:5834077
194:versus
112:versus
103:versus
1276:
1240:
1232:
1190:
1154:
1118:
1083:
1073:
1034:
1026:
990:
982:
962:Cancer
941:
914:
906:
870:
862:
826:
798:
770:
734:
699:
660:
632:
604:
574:
566:
531:
483:
473:
434:
424:
385:
344:
308:
298:
259:
1238:S2CID
1210:(PDF)
1032:S2CID
988:S2CID
912:S2CID
868:S2CID
572:S2CID
237:(PDF)
1274:PMID
1230:PMID
1188:PMID
1152:PMID
1116:PMID
1081:PMID
1024:PMID
980:PMID
939:PMID
904:PMID
860:PMID
824:PMID
820:243A
796:PMID
768:PMID
732:PMID
697:PMID
658:PMID
654:243A
630:PMID
602:PMID
564:PMID
529:PMID
481:PMID
432:PMID
383:PMID
342:PMID
306:PMID
257:PMID
1266:doi
1222:doi
1180:doi
1144:doi
1108:doi
1071:PMC
1063:doi
1016:doi
970:doi
935:303
896:doi
852:doi
792:260
760:doi
724:doi
689:doi
685:135
626:303
556:doi
521:doi
471:PMC
463:doi
422:PMC
414:doi
373:doi
334:doi
296:PMC
288:doi
249:doi
37:.
1294::
1272:.
1262:44
1260:.
1236:.
1228:.
1218:25
1216:.
1212:.
1186:.
1176:43
1174:.
1150:.
1140:45
1138:.
1114:.
1104:44
1102:.
1079:.
1069:.
1059:82
1057:.
1053:.
1030:.
1022:.
1012:33
1010:.
986:.
978:.
966:66
964:.
960:.
933:.
910:.
902:.
892:33
890:.
866:.
858:.
848:37
846:.
818:.
790:.
766:.
756:28
754:.
730:.
720:23
718:.
695:.
683:.
670:^
652:.
624:.
598:55
596:.
584:^
570:.
562:.
552:11
550:.
527:.
517:51
515:.
493:^
479:.
469:.
457:.
453:.
430:.
420:.
408:.
404:.
381:.
369:15
367:.
363:.
340:.
330:42
328:.
304:.
294:.
284:29
282:.
278:.
255:.
245:82
243:.
239:.
1280:.
1268::
1244:.
1224::
1194:.
1182::
1158:.
1146::
1122:.
1110::
1087:.
1065::
1038:.
1018::
994:.
972::
945:.
918:.
898::
874:.
854::
830:.
802:.
774:.
762::
738:.
726::
703:.
691::
664:.
636:.
608:.
578:.
558::
535:.
523::
487:.
465::
459:2
438:.
416::
410:2
389:.
375::
348:.
336::
312:.
290::
263:.
251::
44:)
40:(
Text is available under the Creative Commons Attribution-ShareAlike License. Additional terms may apply.